Within a previously described B cell based cellular cancer vaccine platform, the immunogenicity and anti-tumor effect of these engineered antigens were evaluated by comparing previously described truncated HER2 antigen, K684, that contains limited immunogenic epitopes. Here, ERBB2 is linked to neoplasm.